AstraZeneca (AZN) Stock Rating Reaffirmed by Deutsche Bank

Deutsche Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Monday, November 12th, Marketbeat Ratings reports. They currently have a GBX 6,500 ($84.93) target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the stock. Credit Suisse Group set a GBX 6,350 ($82.97) price target on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, November 9th. JPMorgan Chase & Co. reissued a buy rating on shares of AstraZeneca in a report on Friday, November 9th. Cfra set a GBX 6,200 ($81.01) price target on shares of AstraZeneca and gave the stock a neutral rating in a report on Friday, November 9th. Barclays reissued a top pick rating and issued a GBX 6,800 ($88.85) price target on shares of AstraZeneca in a report on Friday, November 9th. Finally, Goldman Sachs Group set a GBX 4,080 ($53.31) price target on shares of AstraZeneca and gave the stock a sell rating in a report on Thursday, November 8th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and an average target price of GBX 5,927.44 ($77.45).

Shares of AZN traded down GBX 28 ($0.37) during trading hours on Monday, hitting GBX 5,927 ($77.45). The stock had a trading volume of 2,638,281 shares, compared to its average volume of 2,310,000. AstraZeneca has a fifty-two week low of GBX 4,260 ($55.66) and a fifty-two week high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Understanding Compound Annual Growth Rate (CAGR)

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply